Serum BAFF expression in patients with myasthenia gravis

Journal of Neuroimmunology

Volumn 199, Issue 1-2, 2008, Pages 151-154

  Kim, Jee Young ^a   Yang, Young ^b   Moon, Joon Shik ^c   Lee, Eun Young ^d   So, Sun Hwha ^d   Lee, Hong Soo ^a   Park, Kee Duk ^a   Choi, Young Chul ^d  

^a Ewha Womans University School of Medicine   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c MAYO CLINIC   (United States)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

B lymphocyte stimulator; BAFF; Myasthenia gravis (MG)

Indexed keywords

AZATHIOPRINE; B CELL ACTIVATING FACTOR; CHOLINESTERASE INHIBITOR; STEROID;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; B-CELL ACTIVATING FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 47549101395     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.05.010     Document Type: Article

References (11)

1. Cheema G.S., Roschke V., Hilber D.M., and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44 (2001) 1313-1319
2. Ding C., and Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs 7 (2006) 464-472
3. Katirji B., Kaminski H.J., Preston D.C., Ruff R.L., and Shapiro B.E. Neuromuscular Disorders in Clinical Practice (2002), Butterworth-Heinemann, Boston 916-930
4. Mackay F., Silveira P.A., and Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr. Opin. Immunol. 19 (2007) 327-336
5. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., and Kimberly R. The level of BLys (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann. Rheum. Dis. 62 (2003) 168-171
6. Ropper A.H., and Brown R.H. Adams and Victor's Principles of Neurology. 8th ed. (2005), McGraw-Hill, New York 1250-1264
7. Tangye S.G., Bryant V.L., Cuss A.K., and Good K.L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18 (2006) 305-317
8. Thangarajh M., Gomes A., Masterman T., Hillert J., and Hjelmström P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J. Neuroimmunol. 152 (2004) 183-190
9. Thangarajh M., Masterman T., Helgeland L., Rot U., Jonsson M.V., Eide G.E., Pirskanen R., Hillert J., and Jonsson R. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J. Neuroimmunol. 178 (2006) 161-166
10. Thangarajh M., Kisiswa L., Pirskanen R., and Hillert J. The expression of BAFF-binding receptors in not altered in multiple sclerosis or myasthenia gravis. Scand. J. Immunol. 65 (2007) 461-466
11. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., Bastian H., Kimberly R.P., and Zhou T. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166 (2001) 6-10